ASTRAZENECA ENTERS AGREEMENT WITH HANMI PHARMACEUTICAL AND AMNEAL PHARMACEUTICALS IN US NEXIUM PATENT LITIGATION
AstraZeneca today announced it has entered into an agreement with Hanmi Pharmaceutical and affiliates (“Hanmi”) and its US marketing partner Amneal Pharmaceuticals (“Amneal”) to resolve certain issues and appeal others in US Nexium patent litigation regarding Hanmi’s Esomeprazole Strontium 505(b)2 NDA product. The agreement eliminates the need for a trial at the US District Court for the District of New Jersey (“District Court”), thus avoiding considerable trial costs. Under the terms of a Consent Judgment resolving the litigation, Amneal and Hanmi have conceded the validity and
